There was good news for Anglo-Swedish drug major AstraZeneca (LSE: AZN) yesterday, when the firm revealed positive results relating to its anticoagulant Brilinta (ticagrelor) from a blinded review of clinical data from patients in the PLATO trial who had died following coronary artery bypass graft (CABG) surgery.
The blinded review found that, when compared to clopidogrel (French drugmaker Sanofi’s blockbuster blood thinner Plavix) Brilinta was more commonly associated with fewer cardiac, bleeding or infectious complications that directly caused or contributed to death following CABG. These data were presented at the European Society of Cardiology (ESC) congress in Paris, France, on August 29, which was a public holiday in the UK, but this morning, AstraZeneca’s shares rose 2.2% to £28.74.
“These data may help to further understand the factors that contribute to the ability of ticagrelor to provide superior outcomes over clopidogrel in acute coronary syndrome patients, including when a surgical intervention like CABG is required,” said Christoph Varenhorst, a researcher at the Uppsala Clinical Research Center in Sweden.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze